PDF(Pubmed)
Abstract：
There is a dearth of data regarding the safety and timing of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccination of patients on immunosuppressive or immunomodulatory therapies. However, data from other vaccine trials may be extrapolated to get an idea regarding the recommendation of SARS-COV-2 vaccines. All the novel SARS-COV-2 vaccines are non-live, thus ensuring the safety of the vaccines. However, the vaccines may not be able to generate an equipotent immunogenic response in patients receiving immunotherapeutics, in comparison to those who are not. We have attempted to put forward certain statements, with respect to SARS-COV-2 vaccination of patients who are on treatment for different dermatological conditions. However, the risk-benefit ratio must be discussed between the patient and the physician, and the final call should be individualized.
摘要：
关于免疫抑制或免疫调节疗法患者的严重急性呼吸道综合症冠状病毒2（SARS-COV-2）疫苗接种的安全性和时机的数据很少。然而,可以推断其他疫苗试验的数据,以获得关于推荐SARS-COV-2疫苗的想法.所有新型SARS-COV-2疫苗都是非活的，从而确保疫苗的安全性。然而,疫苗可能无法在接受免疫治疗的患者中产生等效的免疫原性反应，与那些没有的人相比。我们试图提出某些声明，关于正在接受不同皮肤病治疗的患者的SARS-COV-2疫苗接种。然而,风险收益比必须在患者和医生之间讨论，最后的呼吁应该是个性化的。
